Join our daily newsletter At The Bell to receive exclusive market insights
- Telix Pharmaceuticals’ (TLX) investigational product, TLX66, has been chosen for research in as phase two academic study of pediatric leukaemia
- London-based Great Ormond Street Hospital (GOSH) has received UK research approval to study TLX66 in children with high-risk leukaemia
- The phase two study will evaluate the safety and efficiency of TLX66
- On the market, Telix is down 2.70 per cent, trading at $6.13 per share at 12:58 pm AEST
Telix Pharmaceuticals’ (TLX) investigational product, TLX66, has been chosen for research in a phase two academic study of pediatric leukaemia.
London-based Great Ormond Street Hospital (GOSH) has received UK research approval to study TLX66 in children with high-risk leukaemia.
The phase two study is to evaluate the safety and efficiency of TLX66 as part of a reduced toxicity conditioning regimen in children and adolescents undergoing allogeneic haematopoietic stem cell transplantation.
Relevant approvals for the study from the Medicines and Healthcare products Regulatory Agency and Administration of Radioactive Substances Advisory Committee have also been received.
Notably, the study is independently funded by the generosity of a philanthropic foundation, with GOSH as the sponsor.
Chief Medical Officer Colin Hayward is looking forward to the trial.
“We are pleased that Great Ormond Street Hospital, an international centre of excellence in child healthcare, has received ethics approval to use this investigational product in an important academic study of children and adolescents with high-risk leukemia,” Dr Hayward said.
“This disease currently has one of the poorest prognoses amongst pediatric
cancers, and we will be closely monitoring progress by the team at GOSH, in line with Telix’s mission to help patients with cancer live longer, better quality lives.”
On the market, Telix is down 2.70 per cent, trading at $6.13 per share at 12:58 pm AEST.
